Targeted Therapeutics for Cancer and Ophthalmology

Corporate Profile
TRACON Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration and fibrotic diseases. We are a leader in the field of endoglin biology and are using our expertise to develop antibodies that bind to the endoglin receptor. Our lead product candidate, TRC105, is an anti-endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with inhibitors of the VEGF pathway. Our other product candidates are TRC205, an anti-endoglin antibody that is in preclinical development for the treatment of fibrotic diseases, and TRC102, a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma. Each of our product candidates is expected to complement currently available therapies.
Stock Quote
TCON (Common Stock)
Exchange:NASDAQ CM
$5.85 - 0.15 (2.50%)
Data as of 10/21/16 3:59 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
October 20, 2016
TRACON Pharmaceuticals Reports Granting of Inducement Awards
October 9, 2016
TRACON Pharmaceuticals Presents Final Updated Phase 1b Results for TRC105 in Combination with Inlyta® in Renal Cell Carcinoma at the ESMO 2016 Congress
October 3, 2016
TRACON Pharmaceuticals Announces Successful Meetings with FDA and EMA for TRC105 (carotuximab) in Angiosarcoma
Upcoming EventsMore >>
There are currently no events scheduled.
Receive Email AlertsE-mail Alert Icon
Sign up to receive email alerts whenever TRACON Pharmaceuticals Inc posts new information to the site. Just enter your email address and click Submit.
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources
Print Page |
Email Page |
RSS Feeds |
Email Alerts |
Contact IR